competitor does not cut the mustard, page-4

It may pay for us to do some research on Osiris and its product, as well as re-read the life scientist material and compare data. From memory Osiris objective for Phase 2 trial was met?
Agree positive/great news would be in our favour.

Just a few snippets not comprehensive as it is late and I should be in bed!


http://www.osiris.com/prod_diabetes.php - Pre-clinical studies first conducted by researchers at Genzyme found that MSCs may have the ability to delay the progression of type 1 diabetes by preserving beta cell function.

http://www.osiris.com/clinical_prochymal_t1dm.php The objective of this Phase 2 study is to evaluate the efficacy and safety of Prochymal in those patients who have been recently diagnosed with type 1 diabetes mellitus (T1DM). T1DM, or juvenile diabetes, is an autoimmune disorder where the immune system attacks and destroys the beta cell

http://www.lifescientist.com.au/article/407018/mesoblast_posts_successful_results_from_diabetes_stem_cell_trial/
“Intravenous injection of our MPCs may not only improve blood glucose control, it may concomitantly reduce the significant risk of heart attacks and death that occurs in patients with Type 2 diabetes,” said Mesoblast CEO, Professor Silviu Itescu. in the pancreas.